Durable response to programmed death-1 (PD-1) blockade in a metastatic gastric cancer patient with mismatch repair deficiency and microsatellite instability | Zendy

Tinghui Wu | Zendy; Emily Han-Chung Hsiue | Zendy; ChangTsu Yuan | Zendy; LiHui Tseng | Zendy; ChiaChi Lin | Zendy; KunHuei Yeh | Zendy

Open Access

Durable response to programmed death-1 (PD-1) blockade in a metastatic gastric cancer patient with mismatch repair deficiency and microsatellite instability

Author(s) -

Tinghui Wu,

Emily Han-Chung Hsiue,

ChangTsu Yuan,

LiHui Tseng,

ChiaChi Lin,

KunHuei Yeh

Publication year - 2016

Publication title -

journal of cancer research and practice

Language(s) - English

Resource type - Journals

eISSN - 2589-0425

pISSN - 2311-3006

DOI - 10.1016/j.jcrpr.2016.11.001

Subject(s) - medicine , microsatellite instability , pembrolizumab , blockade , cancer , colorectal cancer , dna mismatch repair , oncology , pd l1 , refractory (planetary science) , immunotherapy , microsatellite , receptor , biochemistry , allele , chemistry , physics , astrobiology , gene

Mismatch repair deficiency (dMMR) or microsatellite instability (MSI) has been reported as a predictive biomarker for responses to programmed death-1 (PD-1) blockade in metastatic colorectal cancer. A high response rate to anti-PD-1 therapy was observed in other cancer types with MSI. We report a chemotherapy-refractory metastatic gastric cancer patient with dMMR and MSI who responded remarkably well to pembrolizumab, a PD-1 monoclonal antibody. The satisfactory objective response has lasted for more than 24 months as of this report

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research